Exicure, Inc. (NASDAQ:XCUR) Sees Significant Increase in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 506,729 shares, an increase of 7,428.3% from the June 30th total of 6,731 shares. Approximately 16.8% of the shares of the company are sold short. Based on an average daily trading volume, of 2,149,123 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Exicure Price Performance

Shares of XCUR opened at $1.76 on Friday. The firm has a market capitalization of $11.21 million, a PE ratio of -1.14 and a beta of 3.61. The company’s 50-day moving average is $2.40 and its 200-day moving average is $3.62. Exicure has a fifty-two week low of $1.43 and a fifty-two week high of $9.48.

Exicure (NASDAQ:XCUR) last posted its earnings results on Friday, May 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.31.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.